AngioDynamics Files 8-K Report

Ticker: ANGO · Form: 8-K · Filed: Jan 16, 2025 · CIK: 1275187

Angiodynamics Inc 8-K Filing Summary
FieldDetail
CompanyAngiodynamics Inc (ANGO)
Form Type8-K
Filed DateJan 16, 2025
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, regulation-fd, financial-statements

Related Tickers: ANGI

TL;DR

ANGI filed an 8-K, likely regulatory updates. No major news yet.

AI Summary

On January 16, 2025, AngioDynamics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates AngioDynamics is providing updates or disclosures to the SEC, which could contain important information for investors regarding the company's financial status or regulatory compliance.

Risk Assessment

Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain specific material information that would indicate a change in risk.

Key Players & Entities

  • AngioDynamics, Inc. (company) — Registrant
  • January 16, 2025 (date) — Date of Report
  • 14 Plaza Drive, Latham, New York 12110 (address) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.

What is the exact name of the company filing this report?

The exact name of the registrant is AngioDynamics, Inc.

On what date was this report filed?

The report was filed on January 16, 2025.

What is the company's principal executive office address?

The company's principal executive office is located at 14 Plaza Drive, Latham, New York 12110.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Stats: 860 words · 3 min read · ~3 pages · Grade level 14.2 · Accepted 2025-01-16 16:06:21

Key Financial Figures

  • $0.01 — registered Common Stock, par value $0.01 per share ANGO NASDAQ Global Select

Filing Documents

01 – Regulation FD Disclosure

Item 7.01 – Regulation FD Disclosure. On January 16, 2025, James Clemmer, President and Chief Executive Officer, of AngioDynamics, Inc. ("AngioDynamics"), presented at the J.P. Morgan 43rd Annual Healthcare Conference. The presentation slides are furnished herewith as Exhibit 99.1. The presentation slides furnished pursuant to Item 7.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section. Furthermore, the presentation slides shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Forward-Looking Statements

Forward-Looking Statements This document and its attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects", "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of produ

01 – Financial Statements and Exhibits

Item 9.01 – Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Presentation slides for the J.P. Morgan 43rd Annual Healthcare Conference, dated January 16, 2025. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANGIODYNAMICS, INC. (Registrant) Date: January 16, 2025 By: /s/ Lawrence T. Weiss Name: Lawrence T. Weiss Title: Senior Vice President, Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.